Autologous protein solution: a promising solution for osteoarthritis?

Area of Science:

• Orthopedics
• Regenerative Medicine
• Biologics

Background:

• Osteoarthritis (OA) is a leading cause of adult disability, characterized by joint pain and dysfunction.
• Inflammatory cytokines, such as interleukin-1β (IL-1β) and tumor necrosis factor alpha (TNFα), drive OA's destructive cycle.
• Total knee arthroplasty (TKA) outcomes are less predictable in younger patients, increasing interest in biological treatments.

Purpose of the Study:

• To evaluate autologous protein solution (APS) as a less invasive biological treatment for early-stage osteoarthritis.
• To investigate the potential of APS in mitigating the inflammatory processes underlying OA.

Main Methods:

• Autologous protein solution (APS) is derived from a patient's own blood using a proprietary device.
• The device concentrates white blood cells (WBCs), platelets, and plasma proteins, creating a solution rich in growth factors.
• The anti-inflammatory properties of APS target key mediators like IL-1β and TNFα.

Main Results:

• APS contains high levels of growth factors and anti-inflammatory mediators.
• Preclinical studies suggest a single intraarticular injection of APS is a promising approach for early OA.
• APS demonstrates potential in counteracting pro-inflammatory cytokines involved in OA pathogenesis.

Conclusions:

• Autologous protein solution (APS) presents a potential biological treatment option for early-stage osteoarthritis.
• Current evidence, primarily from preclinical research, supports APS's anti-inflammatory effects.
• Additional clinical investigations are necessary to establish APS as a standard OA treatment modality.